Insmed Inc (INSM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Insmed Inc (INSM) has a cash flow conversion efficiency ratio of -0.232x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-219.76 Million) by net assets ($945.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INSM market cap overview for the company's overall valuation and market capitalisation.
Insmed Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Insmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Insmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insmed Inc ranked by their cash flow conversion efficiency. Explore INSM cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
W. R. Berkley Corp
NYSE:WRB
|
0.116x |
|
SIKA AG UNSP.ADR O.N.
F:SIKB
|
N/A |
|
ACS Actividades de Construccion y Servicios SA
MC:ACS
|
0.330x |
|
American Water Works
NYSE:AWK
|
0.052x |
|
PTT Public Company Limited
F:NVA3
|
0.055x |
|
Zijin Mining Group Company Limited
F:FJZ
|
0.031x |
|
Halliburton Company
NYSE:HAL
|
0.075x |
|
PetroChina Company Limited
F:PC6
|
0.065x |
Annual Cash Flow Conversion Efficiency for Insmed Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Insmed Inc from 1999 to 2024. View INSM stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.38 Million | $-683.88 Million | -2.396x | -248.33% |
| 2023-12-31 | $-331.92 Million | $-536.25 Million | 1.616x | +135.48% |
| 2022-12-31 | $87.95 Million | $-400.44 Million | -4.553x | -414.41% |
| 2021-12-31 | $410.47 Million | $-363.30 Million | -0.885x | -11.32% |
| 2020-12-31 | $275.88 Million | $-219.35 Million | -0.795x | +17.00% |
| 2019-12-31 | $261.67 Million | $-250.65 Million | -0.958x | +22.67% |
| 2018-12-31 | $208.27 Million | $-257.98 Million | -1.239x | -180.20% |
| 2017-12-31 | $361.06 Million | $-159.62 Million | -0.442x | +53.45% |
| 2016-12-31 | $154.48 Million | $-146.71 Million | -0.950x | -193.95% |
| 2015-12-31 | $311.70 Million | $-100.70 Million | -0.323x | +6.60% |
| 2014-12-31 | $186.24 Million | $-64.42 Million | -0.346x | -6.23% |
| 2013-12-31 | $143.32 Million | $-46.66 Million | -0.326x | -26.91% |
| 2012-12-31 | $120.88 Million | $-31.01 Million | -0.257x | -14.04% |
| 2011-12-31 | $134.27 Million | $-30.20 Million | -0.225x | -461.80% |
| 2010-12-31 | $192.84 Million | $-7.72 Million | -0.040x | +54.94% |
| 2009-12-31 | $123.91 Million | $-11.01 Million | -0.089x | -102.09% |
| 2008-12-31 | $-2.82 Million | $-11.99 Million | 4.248x | +293.23% |
| 2007-12-31 | $11.49 Million | $-25.25 Million | -2.198x | +27.70% |
| 2006-12-31 | $13.88 Million | $-42.20 Million | -3.041x | -15.31% |
| 2005-12-31 | $10.53 Million | $-27.77 Million | -2.637x | +23.38% |
| 2004-12-31 | $7.24 Million | $-24.90 Million | -3.442x | -738.53% |
| 2003-12-31 | $26.22 Million | $-10.76 Million | -0.410x | +60.04% |
| 2002-12-31 | $23.45 Million | $-24.08 Million | -1.027x | -92.93% |
| 2001-12-31 | $59.70 Million | $-31.78 Million | -0.532x | -140.59% |
| 2000-12-31 | $96.78 Million | $-21.42 Million | -0.221x | +86.35% |
| 1999-12-31 | $4.46 Million | $-7.23 Million | -1.621x | -- |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more